Intermediate-Acting Benzodiazepines
Based on authoritative clinical guidelines, the intermediate-acting benzodiazepines are lorazepam, oxazepam, estazolam, and temazepam, with half-lives ranging from 5-24 hours.
Classification by Duration of Action
The benzodiazepines are pharmacologically classified by their elimination half-lives, which directly determines their duration of action 1:
Intermediate-Acting Benzodiazepines (Half-life 5-24 hours):
- Lorazepam - specifically noted as intermediate-acting and safer in elderly patients and those with hepatic dysfunction 2, 3
- Oxazepam - safer in elderly patients and those with hepatic dysfunction 2, 3
- Estazolam - classified as "short- to intermediate-acting" 1
- Temazepam - classified as "short- to intermediate-acting" 1
For Comparison:
Short-Acting (Half-life <5 hours):
Long-Acting (Half-life >24 hours):
- Diazepam
- Flurazepam (rarely prescribed due to extended half-life and risk of residual daytime drowsiness) 1
- Chlordiazepoxide
- Clonazepam 1
Clinical Implications
The intermediate-acting benzodiazepines offer distinct advantages in specific clinical scenarios:
- Less accumulation during multiple dosing compared to long-acting agents 5
- Reduced risk of residual sedation compared to long-acting benzodiazepines
- Safer profile in vulnerable populations: The intermediate-acting agents (lorazepam, oxazepam) are specifically recommended for elderly patients and those with hepatic impairment because they lack active metabolites and have more predictable clearance 2, 3
- Lower fall risk in elderly compared to long-acting agents
Important Clinical Caveats
Duration of use should be strictly limited. Guidelines consistently recommend benzodiazepines for short-term use only—ideally less than 4 weeks maximum 1, 6. Longer courses risk tolerance, dependence, and withdrawal complications.
Avoid abrupt discontinuation in patients likely to be physically dependent, as this poses risk of withdrawal seizures and other serious complications 7.
The classification "intermediate-acting" refers to pharmacokinetic properties, not necessarily clinical indication. While estazolam and temazepam are FDA-approved specifically for insomnia 1, lorazepam and oxazepam are more commonly used for anxiety disorders and alcohol withdrawal syndrome 2, 3.